nei THIS MONTH IN
PSYCHOPHARMACOLOGY
10% of US Children Have a Serious Emotional Disturbance
September 21, 2017   

A new meta-analysis of population-representative studies revealed that 10% of US children experience a serious emotional disturbance (SED) that is functionally impairing...
 Continue reading (Members only)
FDA Permits Marketing of Mobile Medical Application for Substance Use Disorders
September 20, 2017   

The US FDA has permitted the marketing of the Reset device, the first mobile medical application to help treat substance use disorders...
 Continue reading
Meta-Analysis: What Treatments Are Safe and Effective in Pediatric Anxiety?
September 18, 2017   

A recent meta-analysis compared the effectiveness of cognitive behavioral therapy (CBT) and pharmacotherapy for childhood anxiety disorders...
 Continue reading (Members only)
New Mega-Analysis Supports Efficacy of Antidepressants in Adult Depression
September 12, 2017   

Recently, there has been much debate regarding the efficacy of antidepressants in the treatment of adults with major depressive disorder (MDD) due to the often-high levels of response to placebo in many clinical trials...
 Continue reading
SSRIs, SNRIs Show Small But Significant Benefit for Children and Adolescents With Common Mental Illnesses
September 11, 2017   

There continues to be much debate over the utility and risk-to-benefit ratio of antidepressant use within the pediatric population. In the present meta-analysis, Locher and colleagues investigated the safety and efficacy of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs)...
 Continue reading (Members only)
Evaluating the Evidence for Cannabis as a Therapeutic Option: Focus on Chronic Pain and PTSD
September 7, 2017   

As the medicinal use of cannabis becomes increasingly accepted and legal--at least at the state level--a major concern for the medical community is: what is the evidence regarding the efficacy and safety of cannabis as a treatment for medical and psychiatric disorders? Two recent reviews, commissioned by the Veterans Health Administration and funded by the US Department of Veterans Affairs, addressed this issue specifically for chonic pain and posttraumatic stress disorder (PTSD)...
 Continue reading
Antipsychotic Use in Intellectually Disabled Adults
September 1, 2017   

Antipsychotic medication is frequently being prescribed to individuals with intellectual and developmental disabilities (IDD), often without a psychiatric diagnosis...
 Continue reading (Members only)
Deutetrabenazine Approved to Treat Tardive Dyskinesia
August 30, 2017   

The U.S. Food and Drug Administration (FDA) has approved deutetrabenazine, trade name Austedo, for the treatment of tardive dyskinesia...
 Continue reading
Using Brain Patterns to Predict Treatment Response in PTSD
August 18, 2017   

In a recent study, patients with posttraumatic stress disorder (PTSD) underwent functional magnetic resonance imaging (fMRI) while completing three tasks assessing emotional reactivity and regulation...
 Continue reading (Members only)
Non-Dopaminergic Drug Shows Efficacy in Reducing Negative Symptoms of Schizophrenia
August 13, 2017   

A recent study examined the efficacy, safety, and tolerability of the compound, MIN-101 compared to placebo in patients with schizophrenia...
 Continue reading (Members only)
12345678910...
Top of Page